Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?
Version of Record online: 4 MAY 2011
© 2011 Blackwell Publishing Ltd
Clinical & Experimental Allergy
Volume 41, Issue 10, pages 1337–1340, October 2011
How to Cite
Jensen-Jarolim, E. and Singer, J. (2011), Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?. Clinical & Experimental Allergy, 41: 1337–1340. doi: 10.1111/j.1365-2222.2011.03764.x
- Issue online: 20 SEP 2011
- Version of Record online: 4 MAY 2011
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!